サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1518809

虚血性視神経症治療市場：世界の産業分析、規模、シェア、成長、動向、予測、2024年～2033年

Ischemic Optic Neuropathy Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033

出版日
ページ情報
英文 223 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.91円
虚血性視神経症治療市場：世界の産業分析、規模、シェア、成長、動向、予測、2024年～2033年
出版日: 2024年07月12日
発行: Persistence Market Research
ページ情報: 英文 223 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

Persistence Market Research社はこのほど、虚血性視神経症治療市場に関する包括的なレポートを発表しました。当レポートでは、市場促進要因・動向・機会・課題などの重要な市場力学を徹底的に評価し、市場構造に関する詳細な洞察を提供しています。

主な洞察

  • 虚血性視神経症治療市場規模（2024年）：2億1,370万米ドル
  • 予測市場価値（2033年）：2億8,660万米ドル
  • 世界市場成長率（CAGR 2024年～2033年）：3.3%

虚血性視神経症治療市場：調査範囲

虚血性視神経症（ION）とは、視神経への血流不足が視力低下につながる状態を指します。ION治療市場は、病院、診療所、専門の眼科センター、研究機関を対象としており、薬理学的介入、外科的処置、リハビリ療法など、さまざまな治療アプローチを提供しています。

市場促進要因：

世界の虚血性視神経症治療市場は、血管疾患に罹患しやすい人口の高齢化、IONの主な危険因子である糖尿病と高血圧の有病率の増加、早期発見と介入を容易にする画像診断技術の進歩など、いくつかの要因によって牽引されています。さらに、新規治療の有効性や患者中心のケアモデルに対する医療従事者の意識の高まりが、市場拡大をさらに刺激しています。

市場抑制要因：

有望な成長が見込まれる一方で、虚血性視神経症治療市場は、限られた治療選択肢、先進治療に伴う高額費用、地域によって異なる償還政策などに関連する課題に直面しています。さらに、病態の複雑さや個別化された治療アプローチの必要性が、市場浸透や治療の標準化に対する課題となっています。

市場機会：

虚血性視神経症治療市場は、神経保護薬や遺伝子治療などの新規治療ターゲットに焦点を当てた研究開発が進行していることから、大きな成長機会に恵まれています。さらに、製薬企業、学術機関、ヘルスケアプロバイダーが協力して臨床試験を進め、革新的な治療法を開発することで、市場のダイナミクスと患者の転帰を向上させる態勢が整っています。

本レポートで扱う主な質問

  • 虚血性視神経症治療市場の世界的成長を促進する主な要因は何か？
  • 虚血性視神経症治療市場の競合情勢を形成している治療アプローチと新技術は何か？
  • 虚血性視神経症治療市場に貢献している主要企業はどこで、市場の関連性を維持するためにどのような戦略を採用しているのか？
  • 世界の虚血性視神経症治療市場の新たな動向と将来展望は？

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場範囲/ 分類
  • 市場の定義/ 範囲/ 制限
  • 包含と除外

第3章 主要な市場動向

  • 市場に影響を与える主な動向
  • イノベーション/開発動向

第4章 主要な成功要因

  • 薬物クラスの採用分析
  • 主な規制
  • パイプライン評価
  • 主要企業による主なプロモーション戦略
  • PESTEL分析
  • ポーターの分析
  • バリューチェーン分析

第5章 市場背景

  • マクロ経済要因
  • 予測要因- 関連性と影響
  • 市場力学

第6章 COVID-19危機分析

  • COVID-19と影響分析
    • 薬剤クラス別
    • 投与経路別
    • 疾患タイプ別
    • 流通チャネル別
    • 国別
  • 2024年の市場シナリオ

第7章 世界の虚血性視神経症治療市場の需要分析

  • 過去の市場価値分析、2019年～2023年
  • 現在および将来の市場価値予測、2024年～2033年
    • 前年比成長動向分析
    • 絶対額の機会分析

第8章 世界の虚血性視神経症治療市場分析：薬剤クラス別

  • イントロダクション/主な調査結果
  • 過去の市場規模分析：薬剤クラス別、2019年～2023年
  • 現在および将来の市場規模分析と予測：薬剤クラス別、2024年～2033年
    • コルチコステロイド
    • 代謝拮抗物質
    • 抗凝固剤
    • セロトニン・ノルエピネフリン再取り込み阻害剤（SNRI）
    • 非ステロイド性抗炎症薬（NSAID）
  • 薬剤クラス別の市場の魅力分析

第9章 世界の虚血性視神経症治療市場分析：投与経路別

  • イントロダクション/主な調査結果
  • 過去の市場規模分析：投与経路別、2019年～2023年
  • 現在および将来の市場規模分析と予測：投与経路別、2024年～2033年
    • 経口
    • 注射可能
  • 投与経路別の市場の魅力分析

第10章 世界の虚血性視神経症治療市場分析：疾患タイプ別

  • イントロダクション/主な調査結果
  • 過去の市場規模分析：疾病タイプ別、2019年～2023年
  • 現在および将来の市場規模分析と予測：疾患タイプ別、2024年～2033年
    • 後部虚血性視神経症
    • 前部虚血性視神経症
      • 動脈炎性AION（A-AION）
      • 非動脈炎性AION（NA-AION）
  • 疾病タイプ別の市場の魅力分析

第11章 世界の虚血性視神経症治療市場分析：流通チャネル別

  • イントロダクション/主な調査結果
  • 過去の市場規模分析：流通チャネル別、2019年～2023年
  • 現在および将来の市場規模分析と予測：流通チャネル別、2024年～2033年
    • 病院薬局
    • 小売薬局
    • ドラッグストア
    • オンライン薬局
  • 流通チャネル別の市場の魅力分析

第12章 世界の虚血性視神経症治療市場分析：地域別

  • イントロダクション
  • 過去の市場規模分析：地域別、2019年～2023年
  • 現在および将来の市場規模分析と予測：地域別、2024年～2033年
    • 北米
    • ラテンアメリカ
    • 欧州
    • 東アジア
    • 南アジア
    • オセアニア
    • 中東・アフリカ
  • 地域別の市場の魅力分析

第13章 北米の虚血性視神経症治療市場分析

第14章 ラテンアメリカの虚血性視神経症治療市場分析

第15章 欧州の虚血性視神経症治療市場分析

第16章 東アジアの虚血性視神経症治療市場分析

第17章 南アジアの虚血性視神経症治療市場分析

第18章 オセアニアの虚血性視神経症治療市場

第19章 中東・アフリカの虚血性視神経症治療市場分析

第20章 市場構造分析

  • 企業階層別の市場分析
  • 主要企業の市場シェア分析
  • 市場プレゼンス分析

第21章 競合分析

  • 競合ダッシュボード
  • 競合の詳細
    • AbbVie Inc.（Allergan plc）
    • Eli Lilly and Company
    • GlaxoSmithKline plc.
    • Pfizer Inc.
    • Teva Pharmaceuticals
    • Bausch Health Companies Inc.
    • Bayer AG
    • Bristol-Myers Squibb and Company
    • Sanofi SA
    • F. Hoffmann-La Roche Ltd

第22章 前提と頭字語

第23章 調査手法

目次
Product Code: PMRREP23077

Persistence Market Research has recently released a comprehensive report on the Ischemic Optic Neuropathy Treatment Market. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.

Key Insights:

  • Ischemic Optic Neuropathy Treatment Market Size (2024E): USD 213.7 Mn
  • Projected Market Value (2033F): USD 286.6 Mn
  • Global Market Growth Rate (CAGR 2024 to 2033): 3.3%

Ischemic Optic Neuropathy Treatment Market - Report Scope:

Ischemic Optic Neuropathy (ION) refers to a condition involving the insufficient blood flow to the optic nerve, leading to vision loss. The market for ION treatments caters to hospitals, clinics, specialized ophthalmology centers, and research institutions, offering a range of therapeutic approaches including pharmacological interventions, surgical procedures, and rehabilitative therapies.

Market Growth Drivers:

The global Ischemic Optic Neuropathy Treatment Market is driven by several factors, including the aging population susceptible to vascular diseases, increasing prevalence of diabetes and hypertension, which are major risk factors for ION, and advancements in diagnostic imaging techniques facilitating early detection and intervention. Moreover, growing awareness among healthcare providers about the efficacy of novel treatments and patient-centric care models further stimulate market expansion.

Market Restraints:

Despite promising growth prospects, the Ischemic Optic Neuropathy Treatment Market faces challenges related to limited treatment options, high costs associated with advanced therapies, and varying reimbursement policies across different regions. Additionally, the complexity of the disease pathology and the need for personalized treatment approaches pose challenges for market penetration and treatment standardization.

Market Opportunities:

The Ischemic Optic Neuropathy Treatment Market presents significant growth opportunities driven by ongoing research and development initiatives focused on novel therapeutic targets, including neuroprotective agents and gene therapies. Furthermore, collaborations between pharmaceutical companies, academic institutions, and healthcare providers to advance clinical trials and innovative treatment modalities are poised to enhance market dynamics and patient outcomes.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the Ischemic Optic Neuropathy Treatment Market globally?
  • Which therapeutic approaches and emerging technologies are reshaping the competitive landscape of the Ischemic Optic Neuropathy Treatment Market?
  • Who are the key players contributing to the Ischemic Optic Neuropathy Treatment Market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global Ischemic Optic Neuropathy Treatment Market?

Competitive Intelligence and Business Strategy:

Leading players in the global Ischemic Optic Neuropathy Treatment Market, including major pharmaceutical companies and specialized ophthalmic device manufacturers, focus on innovation, clinical trial advancements, and strategic collaborations to gain a competitive edge. These companies invest in R&D to develop breakthrough therapies, enhance treatment efficacy, and improve patient outcomes. Collaborations with regulatory agencies and patient advocacy groups also play a crucial role in facilitating market access and promoting therapeutic innovations.

Key Companies Profiled:

  • AbbVie Inc.
  • Eli Lily Company
  • GlaxoSmithKline
  • Pfizer Inc.
  • Teva Pharmaceuticals
  • Bausch Health Companies Inc.
  • F. Hoffmann-La Roche AG
  • Bayer AG
  • Sanofi A.S.
  • Bristol-Myers Squibb and Company

Key Segments Covered in Ischemic Optic Neuropathy Treatment Industry Research

Drug Class:

  • Corticosteroids
  • Antimetabolites
  • Anticoagulants
  • Serotonin and norepinephrine reuptake inhibitors (SNRIs)
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Route of Administration:

  • Oral
  • Injectable

Disease Type:

  • Posterior ischemic optic neuropathy
  • Anterior ischemic optic neuropathy

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Innovation / Development Trends

4. Key Success Factors

  • 4.1. Drug Class Adoption Analysis
  • 4.2. Key Regulations
  • 4.3. Pipeline Assessment
  • 4.4. Key promotional Strategies, By Key Players
  • 4.5. PESTEL Analysis
  • 4.6. Porter's Analysis
  • 4.7. Value Chain Analysis

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Outlook
    • 5.1.3. Global Ophthalmic Disease Therapeutics Market Outlook
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Increase in R&D Spending
    • 5.2.2. Growing Lifestyle Disease Prevalence
    • 5.2.3. Cost of Drug Class
    • 5.2.4. Drug Class Adoption Rate
    • 5.2.5. New Drug Class pipeline
    • 5.2.6. Recent Drug Class Launched/approved
    • 5.2.7. Changes in Regulatory Policies
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. COVID-19 and Impact Analysis
    • 6.1.1. By Drug Class
    • 6.1.2. By Route of Administration
    • 6.1.3. By Disease Type
    • 6.1.4. By Distribution Channel
    • 6.1.5. By Country
  • 6.2. 2024 Market Scenario

7. Global Ischemic Optic Neuropathy Treatment Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2033

  • 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2033
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Ischemic Optic Neuropathy Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Drug Class

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Mn) Analysis, By Drug Class, 2019-2023
  • 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2024-2033
    • 8.3.1. Corticosteroids
    • 8.3.2. Antimetabolites
    • 8.3.3. Anticoagulants
    • 8.3.4. Serotonin and norepinephrine reuptake inhibitors (SNRIs)
    • 8.3.5. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • 8.4. Market Attractiveness Analysis By Drug Class

9. Global Ischemic Optic Neuropathy Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Route of Administration

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) Analysis, By Route of Administration, 2019-2023
  • 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2024-2033
    • 9.3.1. Oral
    • 9.3.2. Injectable
  • 9.4. Market Attractiveness Analysis By Route of Administration

10. Global Ischemic Optic Neuropathy Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Disease Type

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Mn) Analysis, By Disease Type, 2019-2023
  • 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Disease Type, 2024-2033
    • 10.3.1. Posterior ischemic optic neuropathy
    • 10.3.2. Anterior ischemic optic neuropathy
      • 10.3.2.1. Arteritic AION (A-AION)
      • 10.3.2.2. Non-Arteritic AION (NA-AION)
  • 10.4. Market Attractiveness Analysis By Disease Type

11. Global Ischemic Optic Neuropathy Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Distribution Channel

  • 11.1. Introduction / Key Findings
  • 11.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2019-2023
  • 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2024-2033
    • 11.3.1. Hospital Pharmacies
    • 11.3.2. Retail Pharmacies
    • 11.3.3. Drug Stores
    • 11.3.4. Online Pharmacies
  • 11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Ischemic Optic Neuropathy Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Region

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
  • 12.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, By Region 2024-2033
    • 12.3.1. North America
    • 12.3.2. Latin America
    • 12.3.3. Europe
    • 12.3.4. East Asia
    • 12.3.5. South Asia
    • 12.3.6. Oceania
    • 12.3.7. Middle East and Africa (MEA)
  • 12.4. Market Attractiveness Analysis By Region

13. North America Ischemic Optic Neuropathy Treatment Market Analysis 2019-2023 and Forecast 2024-2033

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 13.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 13.3.1. By Country
      • 13.3.1.1. U.S.
      • 13.3.1.2. Canada
    • 13.3.2. By Drug Class
    • 13.3.3. By Route of Administration
    • 13.3.4. By Disease Type
    • 13.3.5. By Distribution Channel
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Drug Class
    • 13.4.3. By Route of Administration
    • 13.4.4. By Disease Type
    • 13.4.5. By Distribution Channel
  • 13.5. Market Trends
  • 13.6. Drivers and Restraints - Impact Analysis
  • 13.7. Key Players - Intensity Mapping
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. U.S. Ischemic Optic Neuropathy Treatment Market Analysis
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.1.2.1. By Drug Class
        • 13.8.1.2.2. By Route of Administration
        • 13.8.1.2.3. By Disease Type
        • 13.8.1.2.4. By Distribution Channel
    • 13.8.2. Canada Ischemic Optic Neuropathy Treatment Market Analysis
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.2.2.1. By Drug Class
        • 13.8.2.2.2. By Route of Administration
        • 13.8.2.2.3. By Disease Type
        • 13.8.2.2.4. By Distribution Channel

14. Latin America Ischemic Optic Neuropathy Treatment Market Analysis 2019-2023 and Forecast 2024-2033

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 14.3.1. By Country
      • 14.3.1.1. Mexico
      • 14.3.1.2. Brazil
      • 14.3.1.3. Argentina
      • 14.3.1.4. Rest of Latin America
    • 14.3.2. By Drug Class
    • 14.3.3. By Route of Administration
    • 14.3.4. By Disease Type
    • 14.3.5. By Distribution Channel
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Drug Class
    • 14.4.3. By Route of Administration
    • 14.4.4. By Disease Type
    • 14.4.5. By Distribution Channel
  • 14.5. Market Trends
  • 14.6. Drivers and Restraints - Impact Analysis
  • 14.7. Key Players - Intensity Mapping
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. Mexico Ischemic Optic Neuropathy Treatment Market Analysis
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.1.2.1. By Drug Class
        • 14.8.1.2.2. By Route of Administration
        • 14.8.1.2.3. By Disease Type
        • 14.8.1.2.4. By Distribution Channel
    • 14.8.2. Brazil Ischemic Optic Neuropathy Treatment Market Analysis
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.2.2.1. By Drug Class
        • 14.8.2.2.2. By Route of Administration
        • 14.8.2.2.3. By Disease Type
        • 14.8.2.2.4. By Distribution Channel
    • 14.8.3. Argentina Ischemic Optic Neuropathy Treatment Market Analysis
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.3.2.1. By Drug Class
        • 14.8.3.2.2. By Route of Administration
        • 14.8.3.2.3. By Disease Type
        • 14.8.3.2.4. By Distribution Channel

15. Europe Ischemic Optic Neuropathy Treatment Market Analysis 2019-2023 and Forecast 2024-2033

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 15.3.1. By Country
      • 15.3.1.1. Germany
      • 15.3.1.2. Italy
      • 15.3.1.3. France
      • 15.3.1.4. U.K.
      • 15.3.1.5. Spain
      • 15.3.1.6. BENELUX
      • 15.3.1.7. Russia
      • 15.3.1.8. Rest of Europe
    • 15.3.2. By Drug Class
    • 15.3.3. By Route of Administration
    • 15.3.4. By Disease Type
    • 15.3.5. By Distribution Channel
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Drug Class
    • 15.4.3. By Route of Administration
    • 15.4.4. By Disease Type
    • 15.4.5. By Distribution Channel
  • 15.5. Market Trends
  • 15.6. Drivers and Restraints - Impact Analysis
  • 15.7. Key Players - Intensity Mapping
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. Germany Ischemic Optic Neuropathy Treatment Market Analysis
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.1.2.1. By Drug Class
        • 15.8.1.2.2. By Route of Administration
        • 15.8.1.2.3. By Disease Type
        • 15.8.1.2.4. By Distribution Channel
    • 15.8.2. Italy Ischemic Optic Neuropathy Treatment Market Analysis
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.2.2.1. By Drug Class
        • 15.8.2.2.2. By Route of Administration
        • 15.8.2.2.3. By Disease Type
        • 15.8.2.2.4. By Distribution Channel
    • 15.8.3. France Ischemic Optic Neuropathy Treatment Market Analysis
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.3.2.1. By Drug Class
        • 15.8.3.2.2. By Route of Administration
        • 15.8.3.2.3. By Disease Type
        • 15.8.3.2.4. By Distribution Channel
    • 15.8.4. U.K. Ischemic Optic Neuropathy Treatment Market Analysis
      • 15.8.4.1. Introduction
      • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.4.2.1. By Drug Class
        • 15.8.4.2.2. By Route of Administration
        • 15.8.4.2.3. By Disease Type
        • 15.8.4.2.4. By Distribution Channel
    • 15.8.5. Spain Ischemic Optic Neuropathy Treatment Market Analysis
      • 15.8.5.1. Introduction
      • 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.5.2.1. By Drug Class
        • 15.8.5.2.2. By Route of Administration
        • 15.8.5.2.3. By Disease Type
        • 15.8.5.2.4. By Distribution Channel
    • 15.8.6. BENELUX Ischemic Optic Neuropathy Treatment Market Analysis
      • 15.8.6.1. Introduction
      • 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.6.2.1. By Drug Class
        • 15.8.6.2.2. By Route of Administration
        • 15.8.6.2.3. By Disease Type
        • 15.8.6.2.4. By Distribution Channel
    • 15.8.7. Russia Ischemic Optic Neuropathy Treatment Market Analysis
      • 15.8.7.1. Introduction
      • 15.8.7.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.7.2.1. By Drug Class
        • 15.8.7.2.2. By Route of Administration
        • 15.8.7.2.3. By Disease Type
        • 15.8.7.2.4. By Distribution Channel

16. East Asia Ischemic Optic Neuropathy Treatment Market Analysis 2019-2023 and Forecast 2024-2033

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 16.3.1. By Country
      • 16.3.1.1. China
      • 16.3.1.2. Japan
      • 16.3.1.3. South Korea
    • 16.3.2. By Drug Class
    • 16.3.3. By Route of Administration
    • 16.3.4. By Disease Type
    • 16.3.5. By Distribution Channel
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Drug Class
    • 16.4.3. By Route of Administration
    • 16.4.4. By Disease Type
    • 16.4.5. By Distribution Channel
  • 16.5. Market Trends
  • 16.6. Drivers and Restraints - Impact Analysis
  • 16.7. Key Players - Intensity Mapping
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. China Ischemic Optic Neuropathy Treatment Market Analysis
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.1.2.1. By Drug Class
        • 16.8.1.2.2. By Route of Administration
        • 16.8.1.2.3. By Disease Type
        • 16.8.1.2.4. By Distribution Channel
    • 16.8.2. Japan Ischemic Optic Neuropathy Treatment Market Analysis
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.2.2.1. By Drug Class
        • 16.8.2.2.2. By Route of Administration
        • 16.8.2.2.3. By Disease Type
        • 16.8.2.2.4. By Distribution Channel
    • 16.8.3. South Korea Ischemic Optic Neuropathy Treatment Market Analysis
      • 16.8.3.1. Introduction
      • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.3.2.1. By Drug Class
        • 16.8.3.2.2. By Route of Administration
        • 16.8.3.2.3. By Disease Type
        • 16.8.3.2.4. By Distribution Channel

17. South Asia Ischemic Optic Neuropathy Treatment Market Analysis 2019-2023 and Forecast 2024-2033

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 17.3.1. By Country
      • 17.3.1.1. India
      • 17.3.1.2. Indonesia
      • 17.3.1.3. Malaysia
      • 17.3.1.4. Thailand
      • 17.3.1.5. Rest of South Asia
    • 17.3.2. By Drug Class
    • 17.3.3. By Route of Administration
    • 17.3.4. By Disease Type
    • 17.3.5. By Distribution Channel
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Drug Class
    • 17.4.3. By Route of Administration
    • 17.4.4. By Disease Type
    • 17.4.5. By Distribution Channel
  • 17.5. Market Trends
  • 17.6. Drivers and Restraints - Impact Analysis
  • 17.7. Key Players - Intensity Mapping
  • 17.8. Country Level Analysis & Forecast
    • 17.8.1. India Ischemic Optic Neuropathy Treatment Market Analysis
      • 17.8.1.1. Introduction
      • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.1.2.1. By Drug Class
        • 17.8.1.2.2. By Route of Administration
        • 17.8.1.2.3. By Disease Type
        • 17.8.1.2.4. By Distribution Channel
    • 17.8.2. Indonesia Ischemic Optic Neuropathy Treatment Market Analysis
      • 17.8.2.1. Introduction
      • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.2.2.1. By Drug Class
        • 17.8.2.2.2. By Route of Administration
        • 17.8.2.2.3. By Disease Type
        • 17.8.2.2.4. By Distribution Channel
    • 17.8.3. Malaysia Ischemic Optic Neuropathy Treatment Market Analysis
      • 17.8.3.1. Introduction
      • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.3.2.1. By Drug Class
        • 17.8.3.2.2. By Route of Administration
        • 17.8.3.2.3. By Disease Type
        • 17.8.3.2.4. By Distribution Channel
    • 17.8.4. Thailand Ischemic Optic Neuropathy Treatment Market Analysis
      • 17.8.4.1. Introduction
      • 17.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.4.2.1. By Drug Class
        • 17.8.4.2.2. By Route of Administration
        • 17.8.4.2.3. By Disease Type
        • 17.8.4.2.4. By Distribution Channel

18. Oceania Ischemic Optic Neuropathy Treatment Market 2019-2023 and Forecast 2024-2033

  • 18.1. Introduction
  • 18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 18.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 18.3.1. By Country
      • 18.3.1.1. Australia
      • 18.3.1.2. New Zealand
    • 18.3.2. By Drug Class
    • 18.3.3. By Route of Administration
    • 18.3.4. By Disease Type
    • 18.3.5. By Distribution Channel
  • 18.4. Market Attractiveness Analysis
    • 18.4.1. By Country
    • 18.4.2. By Drug Class
    • 18.4.3. By Route of Administration
    • 18.4.4. By Disease Type
    • 18.4.5. By Distribution Channel
  • 18.5. Market Trends
  • 18.6. Drivers and Restraints - Impact Analysis
  • 18.7. Key Players - Intensity Mapping
  • 18.8. Country Level Analysis & Forecast
    • 18.8.1. Australia Ischemic Optic Neuropathy Treatment Market Analysis
      • 18.8.1.1. Introduction
      • 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.1.2.1. By Drug Class
        • 18.8.1.2.2. By Route of Administration
        • 18.8.1.2.3. By Disease Type
        • 18.8.1.2.4. By Distribution Channel
    • 18.8.2. New Zealand Ischemic Optic Neuropathy Treatment Market Analysis
      • 18.8.2.1. Introduction
      • 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.2.2.1. By Drug Class
        • 18.8.2.2.2. By Route of Administration
        • 18.8.2.2.3. By Disease Type
        • 18.8.2.2.4. By Distribution Channel

19. Middle East and Africa (MEA) Ischemic Optic Neuropathy Treatment Market Analysis 2019-2023 and Forecast 2024-2033

  • 19.1. Introduction
  • 19.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 19.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 19.3.1. By Country
      • 19.3.1.1. GCC Countries
      • 19.3.1.2. Turkey
      • 19.3.1.3. North Africa
      • 19.3.1.4. South Africa
      • 19.3.1.5. Rest of Middle East and Africa
    • 19.3.2. By Drug Class
    • 19.3.3. By Route of Administration
    • 19.3.4. By Disease Type
    • 19.3.5. By Distribution Channel
  • 19.4. Market Attractiveness Analysis
    • 19.4.1. By Country
    • 19.4.2. By Drug Class
    • 19.4.3. By Route of Administration
    • 19.4.4. By Disease Type
    • 19.4.5. By Distribution Channel
  • 19.5. Market Trends
  • 19.6. Drivers and Restraints - Impact Analysis
  • 19.7. Key Players - Intensity Mapping
  • 19.8. Country Level Analysis & Forecast
    • 19.8.1. GCC Countries Ischemic Optic Neuropathy Treatment Market Analysis
      • 19.8.1.1. Introduction
      • 19.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.1.2.1. By Drug Class
        • 19.8.1.2.2. By Route of Administration
        • 19.8.1.2.3. By Disease Type
        • 19.8.1.2.4. By Distribution Channel
    • 19.8.2. Turkey Ischemic Optic Neuropathy Treatment Market Analysis
      • 19.8.2.1. Introduction
      • 19.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.2.2.1. By Drug Class
        • 19.8.2.2.2. By Route of Administration
        • 19.8.2.2.3. By Disease Type
        • 19.8.2.2.4. By Distribution Channel
    • 19.8.3. South Africa Ischemic Optic Neuropathy Treatment Market Analysis
      • 19.8.3.1. Introduction
      • 19.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.3.2.1. By Drug Class
        • 19.8.3.2.2. By Route of Administration
        • 19.8.3.2.3. By Disease Type
        • 19.8.3.2.4. By Distribution Channel
    • 19.8.4. North Africa Ischemic Optic Neuropathy Treatment Market Analysis
      • 19.8.4.1. Introduction
      • 19.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.4.2.1. By Drug Class
        • 19.8.4.2.2. By Route of Administration
        • 19.8.4.2.3. By Disease Type
        • 19.8.4.2.4. By Distribution Channel

20. Market Structure Analysis

  • 20.1. Market Analysis by Tier of Companies
  • 20.2. Market Share Analysis of Top Players
  • 20.3. Market Presence Analysis

21. Competition Analysis

  • 21.1. Competition Dashboard
  • 21.2. Competition Deep Dive
    • 21.2.1. AbbVie Inc. (Allergan plc)
      • 21.2.1.1. Overview
      • 21.2.1.2. Drug Class Portfolio
      • 21.2.1.3. Sales Footprint
      • 21.2.1.4. Key Financials
      • 21.2.1.5. SWOT Analysis
      • 21.2.1.6. Strategy Overview
        • 21.2.1.6.1. Marketing Strategy
        • 21.2.1.6.2. Service Strategy
        • 21.2.1.6.3. Channel Strategy
    • 21.2.2. Eli Lilly and Company
      • 21.2.2.1. Overview
      • 21.2.2.2. Drug Class Portfolio
      • 21.2.2.3. Sales Footprint
      • 21.2.2.4. Key Financials
      • 21.2.2.5. SWOT Analysis
      • 21.2.2.6. Strategy Overview
        • 21.2.2.6.1. Marketing Strategy
        • 21.2.2.6.2. Service Strategy
        • 21.2.2.6.3. Channel Strategy
    • 21.2.3. GlaxoSmithKline plc.
      • 21.2.3.1. Overview
      • 21.2.3.2. Drug Class Portfolio
      • 21.2.3.3. Sales Footprint
      • 21.2.3.4. Key Financials
      • 21.2.3.5. SWOT Analysis
      • 21.2.3.6. Strategy Overview
        • 21.2.3.6.1. Marketing Strategy
        • 21.2.3.6.2. Service Strategy
        • 21.2.3.6.3. Channel Strategy
    • 21.2.4. Pfizer Inc.
      • 21.2.4.1. Overview
      • 21.2.4.2. Drug Class Portfolio
      • 21.2.4.3. Sales Footprint
      • 21.2.4.4. Key Financials
      • 21.2.4.5. SWOT Analysis
      • 21.2.4.6. Strategy Overview
        • 21.2.4.6.1. Marketing Strategy
        • 21.2.4.6.2. Service Strategy
        • 21.2.4.6.3. Channel Strategy
    • 21.2.5. Teva Pharmaceuticals
      • 21.2.5.1. Overview
      • 21.2.5.2. Drug Class Portfolio
      • 21.2.5.3. Sales Footprint
      • 21.2.5.4. Key Financials
      • 21.2.5.5. SWOT Analysis
      • 21.2.5.6. Strategy Overview
        • 21.2.5.6.1. Marketing Strategy
        • 21.2.5.6.2. Service Strategy
        • 21.2.5.6.3. Channel Strategy
    • 21.2.6. Bausch Health Companies Inc.
      • 21.2.6.1. Overview
      • 21.2.6.2. Drug Class Portfolio
      • 21.2.6.3. Sales Footprint
      • 21.2.6.4. Key Financials
      • 21.2.6.5. SWOT Analysis
      • 21.2.6.6. Strategy Overview
        • 21.2.6.6.1. Marketing Strategy
        • 21.2.6.6.2. Service Strategy
        • 21.2.6.6.3. Channel Strategy
    • 21.2.7. Bayer AG
      • 21.2.7.1. Overview
      • 21.2.7.2. Drug Class Portfolio
      • 21.2.7.3. Sales Footprint
      • 21.2.7.4. Key Financials
      • 21.2.7.5. SWOT Analysis
      • 21.2.7.6. Strategy Overview
        • 21.2.7.6.1. Marketing Strategy
        • 21.2.7.6.2. Service Strategy
        • 21.2.7.6.3. Channel Strategy
    • 21.2.8. Bristol-Myers Squibb and Company
      • 21.2.8.1. Overview
      • 21.2.8.2. Drug Class Portfolio
      • 21.2.8.3. Sales Footprint
      • 21.2.8.4. Key Financials
      • 21.2.8.5. SWOT Analysis
      • 21.2.8.6. Strategy Overview
        • 21.2.8.6.1. Marketing Strategy
        • 21.2.8.6.2. Service Strategy
        • 21.2.8.6.3. Channel Strategy
    • 21.2.9. Sanofi S.A.
      • 21.2.9.1. Overview
      • 21.2.9.2. Drug Class Portfolio
      • 21.2.9.3. Sales Footprint
      • 21.2.9.4. Key Financials
      • 21.2.9.5. SWOT Analysis
      • 21.2.9.6. Strategy Overview
        • 21.2.9.6.1. Marketing Strategy
        • 21.2.9.6.2. Service Strategy
        • 21.2.9.6.3. Channel Strategy
    • 21.2.10. F. Hoffmann-La Roche Ltd
      • 21.2.10.1. Overview
      • 21.2.10.2. Drug Class Portfolio
      • 21.2.10.3. Sales Footprint
      • 21.2.10.4. Key Financials
      • 21.2.10.5. SWOT Analysis
      • 21.2.10.6. Strategy Overview
        • 21.2.10.6.1. Marketing Strategy
        • 21.2.10.6.2. Service Strategy
        • 21.2.10.6.3. Channel Strategy

22. Assumptions and Acronyms Used

23. Research Methodology